ReviewNature reviews. Nephrology2015
MicroRNAs in kidney physiology and disease.
Review in Nature reviews. Nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
191 citing papers in PubMed, 1 synthesis or guideline pooled it, 352 citations in OpenAlex.
- Panel miRNAs are potential diagnostic markers for chronic kidney diseases: a systematic review and meta-analysis.BMC nephrology · 2024Pooled it
- Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease.International journal of molecular sciences · 2025Trial
- Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.American journal of physiology. Heart and circulatory physiology · 2015Trial
- Point-of-Care Assessment of Kidney Function in Chronic Kidney Disease: Current Technologies and Future Perspectives.Medical sciences (Basel, Switzerland) · 2026Review
- Exosomal miR-20a-5p derived from renal tubular epithelial cells regulates podocyte cytoskeletal remodeling via targeting myosin X in diabetic kidney disease.Diabetology & metabolic syndrome · 2026Article
- Analysis of Circulating and Urinary Levels of hsa-miRNA-770-5p in Diabetic Nephropathy.Biomolecules · 2026Article
- Technical considerations and review of urinary microRNAs as biomarkers for chronic kidney disease in dogs and cats.Veterinary clinical pathology · 2025Review
- miR-1225-3p regulates fibrosis in mesangial cells via SMURF2-mediated ubiquitination of ChREBP in diabetic kidney disease.Renal failure · 2025Article
- Low circulating miR-190a-5p predicts progression of chronic kidney disease.Nature communications · 2025Article
- Non-Protein-Coding RNA and Acute Kidney Injury: New Developments from Pathogenesis to Potential Biomarker.Genes · 2025Review
- The key role of miR‑378 in kidney diseases (Review).Molecular medicine reports · 2025Review
- Urinary and Plasma miRNAs in the Early Detection of Acute Kidney Injury and Their Possible Role as Therapeutic Targets.Journal of clinical medicine · 2025Review
- Circulating extracellular RNAs, myocardial remodeling, and elevated BMI in patients with acute coronary syndrome.American journal of cardiovascular disease · 2025Article
- Identification and Functional Mechanism Verification of Novel MicroRNAs Associated with the Fibrosis Progression in Chronic Kidney Disease.Biochemical genetics · 2024Article
- Circulating microRNAs as markers for scrub typhus-associated acute kidney injury.Kidney research and clinical practice · 2024Article
- Relationship between circulating thrombospondin-1 messenger ribonucleic acid and microribonucleic acid-194 levels in Chinese patients with type 2 diabetic kidney disease: The outcomes of a case-control study.Journal of diabetes investigation · 2024Article
- microRNA profile of endometrial cancer from Indian patients-identification of potential biomarkers for prognosis.Biochemistry and biophysics reports · 2024Article
- Epigenetic mechanisms differentially regulate blood pressure and renal dysfunction in male and female Npr1 haplotype mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Preanalytical considerations in quantifying circulating miRNAs that predict end-stage kidney disease in diabetes.JCI insight · 2024Article
- Integrin-linked kinase mRNA expression in circulating mononuclear cells as a biomarker of kidney and vascular damage in experimental chronic kidney disease.Cell communication and signaling : CCS · 2024Article
131 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression. They have important roles during kidney development, homeostasis and disease. In particular, miRNAs participate in the onset and progression of tubulointerstitial sclerosis and end-stage glomerular lesions that occur in various forms of chronic kidney disease (CKD). Therefore, miRNAs represent potential new therapeutic targets for a debilitating disease that continues to increase in prevalence worldwide and for which fully effective therapies are lacking. Several lines of research aimed at improving common CKD diagnostic tools and avoiding invasive kidney biopsies have also identified circulating miRNAs as possible diagnostic and even prognostic biomarkers of kidney disease. This Review discusses current understanding of the function of miRNAs in CKD, focusing on functions specifically involved in the transforming growth factor β1 pathway, which is activated in CKD. miRNAs that, according to available evidence, seem to be involved in diabetic nephropathy, IgA nephropathy, lupus nephritis, polycystic kidney disease and graft rejection, are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.